Similar articles

• National Institutes of Health. Points to consider in the design and submission of human somatic-cell gene therapy protocols. Human Gene Therapy Subcommittee, NIH Recombinant DNA Advisory Committee. Adopted September 29, 1986.

  [No authors listed] [No authors listed] Recomb DNA Tech Bull. 1986 Dec;9(4):221-42. Recomb DNA Tech Bull. 1986. PMID: 3469693 No abstract available.
• Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee, Points to Consider Subcommittee. Minutes of meeting, March 31, 1989.

  [No authors listed] [No authors listed] Recomb DNA Tech Bull. 1989 Sep;12(3):151-70. Recomb DNA Tech Bull. 1989. PMID: 2595016 No abstract available.
• Recombinant DNA research; actions under guidelines; notice -- E. Points to consider for protocols for the transfer of recombinant DNA into the genome of human subjects.

  U.S. National Institutes of Health. U.S. National Institutes of Health. Fed Regist. 1990 Mar 1;55(41):7443-7. Fed Regist. 1990. PMID: 11645685 No abstract available.
• Regulatory concerns in human gene therapy.

  Epstein SL. Epstein SL. Hum Gene Ther. 1991 Fall;2(3):243-9. doi: 10.1089/hum.1991.2.3-243. Hum Gene Ther. 1991. PMID: 1751592 Review.
• Human gene therapy: ethics and public policy.

  Walters L. Walters L. Hum Gene Ther. 1991 Summer;2(2):115-22. doi: 10.1089/hum.1991.2.2-115. Hum Gene Ther. 1991. PMID: 1911932 Review.